Article info
PDFShort Report
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
- ↵a 646-888-4589 postowm{at}mskcc.org
- ↵b mmanuel{at}immunid.com
- ↵c wongp{at}mskcc.org
- ↵d yuanj{at}mskcc.org
- ↵e dongz{at}mskcc.org
- ↵f liuc3{at}mskcc.org
- ↵g sperez{at}immunid.com
- ↵h itanneau{at}immunid.com
- ↵i mnoel{at}immunid.com
- ↵j acourtier{at}immunid.com
- ↵k npasqual{at}immunid.com
- ↵l wolchokj{at}mskcc.org
Citation
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
Publication history
- Received March 19, 2015
- Accepted May 8, 2015
- First published June 16, 2015.
Online issue publication
February 15, 2021
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s). 2016 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.